reports
J M Smucker Co: 1 director
A director at J M Smucker Co sold 5,117 shares at 116.260USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Be...
NEW YORK--(BUSINESS WIRE)-- , a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See . As detailed below, the complaint...
Eli Lilly & Co: 1 director
A director at Eli Lilly & Co sold 1,000 shares at 818.240USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
- Research Team ACF
ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...
Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
- Blair Levin
NSR Policy: What Does BEAD State Bidding Tell Us?
Last week, we provided several notes analyzing how Congressional Republicans and the Administration, as well as others, were debating changes in the BEAD program. While that rhetoric pointed to significant changes ahead, the states have been proceeding under the existing rules set in the Biden Administration, making significant progress in ways generally not reflected in the DC discussions. In this note, we summarize the state activity and ISP bidding to date. We analyze what the state activi...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
In last week's 3/04/25 Compass, we discussed our expectation for near-term downside as the S&P 500 and Nasdaq 100 (QQQ) displayed several bearish short-term developments. The downward pressure has taken out many of the support levels that we outlined, including the bottom of the range at both 5770-5850 and 5600-5670. However a failure to recover above thses levels in the next few days would suggest the markets (S&P 500 and the Nasdaq) have made a top. As we outlined last week, we would need the ...
- Blair Levin
NSR Policy: BEAD Adjustments Certain but Details Still Cloudy
Yesterday, we published a note on whether T, VZ/FYBR and CHTR or Musk will come out on top with revisions to the BEAD program that Republicans are contemplating. As we noted, there are numerous changes we felt confident Republicans would do, such as removing a fiber preference, that will have no material impact on publicly traded companies. But there are several other changes that could, including whether the federal government will impose a high-cost threshold on states that will shift funds f...
- Blair Levin
Will T, VZ/FYBR and CHTR or Musk Come Out on Top with BEAD Revisions?
While the Trump Administration and Congressional Republicans have sent some signals about how they will revise the $42.5 Billion Biden Broadband Equity, Access and Deployment (BEAD) program, there has been no definitive word yet on key issues regarding those revisions. That may change today, when there is a congressional hearing on the program. In this note, we review the potential changes from the investor perspective, with a focus on the relative benefits to wireline broadband providers (par...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Near-Term Downside Likely Following False Breakouts Our long-term outlook remains bullish as long as the S&P 500 remains above 5770-5850 and 5600-5670 (worst case), and we are buyers at these levels. With that said, we see potential for near-term downside as the S&P 500, Nasdaq 100 (QQQ), and FANG+ (FNGS) (1) could not decisively break out to new highs, (2) display bearish false breakouts, (3) have fallen back into their 2+ month trading ranges, (4) are violating their 1+ month uptrends, and (5...
LLY ELI LILLY AND COMPANY
CFSL COCA-COLA FEMSA SAB DE CV (ADR)
JNJ JOHNSON & JOHNSON
BMY BRISTOL-MYERS SQUIBB COMPANY
AKOB EMBOTELLADORA ANDINA S.A. SERIES B ADS
FMX FOMENTO ECONOMICO MEXICANO S.A.B. DE C.V. ADS
BMTA BRITISH AMERICAN TOBACCO PLC ADS
PM PHILIP MORRIS INTERNATIONAL INC.
ABBV ABBVIE INC.
CCHGY COCA-COLA HBC AG
ABT ABBOTT LABORATORIES
AZN ASTRAZENECA PLC ADS
GSK. GLAXOSMITHKLINE PLC CEDEAR
IMBBY IMPERIAL BRANDS PLC
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
AMN AMN HEALTHCARE SERVICES INC.
TSN TYSON FOODS INC. CLASS A
PNM PNM RESOURCES INC.
OGE OGE ENERGY CORP.
MNST MONSTER BEVERAGE CORPORATION
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
LNT ALLIANT ENERGY CORP
KHC KRAFT HEINZ COMPANY
HSY HERSHEY COMPANY
GIS GENERAL MILLS INC.
FE FIRSTENERGY CORP.
ED CONSOLIDATED EDISON INC.
DUK DUKE ENERGY CORPORATION
D DOMINION ENERGY INC
CPB CAMPBELL SOUP COMPANY
CAG CONAGRA BRANDS INC.
GASS STEALTHGAS
SJM J.M. SMUCKER COMPANY
IRTC IRHYTHM TECHNOLOGIES INC.
NOMDN NOMAD FOODS LTD.
SOI SOLARIS OILFIELD INFRASTRUCTURE
CELH CELSIUS HOLDINGS INC.
KDP KEURIG DR PEPPER INC.
CWAN CLEARWATER ANALYTICS HLDGS INC
KVUE KENVUE INC
WAY WAYSTAR HOLDING CORP
PRMB PRIMO BRANDS CORP
- Blair Levin
- Jonathan Chaplin
Carriers could spend $180BN on spectrum over the next four years
In this note we cover the potential timing of all the major spectrum auctions and transactions that could occur during the current administration, the amount of financial capacity the carriers have for purchasing this spectrum, and the intrinsic value of the spectrum. The analysis has important implications for EchoStar and for the three national carriers.
- Jonathan Chaplin
Autumn for Broadband 4Q24
In this installment of our Autumn for Broadband series, we provide a quick update on trends in the broadband market based on what we have seen from the companies that have reported so far. Adjusted for ACP, trends have improved again with net adds flat vs. last year. We expect organic net adds to recover next year due to lack of ACP headwind. Though the recovery could be impacted by immigration related headwinds.
- Jonathan Chaplin
Thoughts on Altafiber
Based on press reports from a couple of weeks ago, Altafiber has hired advisors for a strategic review. This may not be new; there were rumors that Altafiber was up for sale while the Frontier process was underway. This note explores the assets, the competitive dynamics in their markets, their end-state penetration, and their value. We are mostly using this as a vehicle to preview some of the new features that the Data Analytics team have built into Broadband Insights over the last three mont...
- Blair Levin
NSR Policy Spectrum Battles: A Field Guide
In 2025, the federal government will address multiple issues related to spectrum. While not all the issues will be resolved by the end of the year, the policy and political processes related to specific bands will provide greater clarity about the direction of policy, and the winners and losers, throughout the year.
Moody's Ratings assigns Aa3 rating to Eli Lilly's notes; stable outloo...
Moody's Ratings (Moody's) assigned an Aa3 rating to the new senior unsecured notes offering of Eli Lilly and Company ("Lilly"). There are no changes to Lilly's existing ratings including the Aa3 senior unsecured notes ratings and issuer rating, the (P)Aa3 senior unsecured shelf, the (P)Aa3 senior un...
Merck & Co Inc: 3 directors
Three Directors at Merck & Co Inc bought/sold after exercising options 20,194 shares at between 88.250USD and 88.755USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all...
Moody's Ratings upgrades Eli Lilly's rating to Aa3; outlook is stable
Moody's Ratings (Moody's) upgraded the senior unsecured notes ratings and issuer rating of Eli Lilly and Company ("Lilly") to Aa3 from A1 and affirmed the Prime-1 short-term rating. At the same time, we upgraded the senior unsecured shelf to (P)Aa3 from (P)A1, and the senior unsecured medium term no...
- Jonathan Chaplin
- Jonathan Chaplin
Winter for Wireless
Four of the five carriers that have reported so far expect to increase or maintain net adds in 2025. The sell-side has taken them at their word; consensus expectations reflect a sharp increase in adds for the group in 2025. We think net adds will decline in 2025. Somebody will miss expectations, potentially by a lot. We walk through who is most at risk of missing on adds or EBITDA in this note.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.